KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Inventory (2016 - 2024)

Nektar Therapeutics (NKTR) has 15 years of Inventory data on record, last reported at $14.5 million in Q2 2024.

  • For Q2 2024, Inventory fell 30.08% year-over-year to $14.5 million; the TTM value through Jun 2024 reached $14.5 million, down 30.08%, while the annual FY2023 figure was $16.1 million, 16.15% down from the prior year.
  • Inventory reached $14.5 million in Q2 2024 per NKTR's latest filing, down from $16.2 million in the prior quarter.
  • Across five years, Inventory topped out at $20.7 million in Q2 2023 and bottomed at $12.6 million in Q2 2020.
  • Average Inventory over 5 years is $16.2 million, with a median of $15.6 million recorded in 2021.
  • Peak YoY movement for Inventory: soared 31.58% in 2023, then tumbled 30.08% in 2024.
  • A 5-year view of Inventory shows it stood at $15.3 million in 2020, then increased by 3.33% to $15.8 million in 2021, then increased by 21.52% to $19.2 million in 2022, then fell by 16.15% to $16.1 million in 2023, then fell by 10.16% to $14.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Inventory were $14.5 million in Q2 2024, $16.2 million in Q1 2024, and $16.1 million in Q4 2023.